Analysis of EVs from Patients with Advanced Pancreatic Cancer Identifies Antigens and MiRNAs with Predictive Value

Overview

Journal Mol Ther Methods Clin Dev

Publisher Cell Press

Date 2023 Jun 5

PMID 37273899

Authors

Ivan Vannini

Tania Rossi

Mattia Melloni

Martina Valgiusti

Milena Urbini

Alessandro Passardi

Giulia Bartolini

Chiara Gallio

Irene Azzali

Sara Bandini

Valentina Ancarani

Lorenzo Montanaro

Giovanni Luca Frassineti

Francesco Fabbri

Ilario Giovanni Rapposelli

Affiliations

Soon will be listed here.

Abstract

The identification of predictive factors for treatment of pancreatic cancer (PC) is an unmet clinical need. In the present work, we analyzed blood-derived extracellular vesicles (EVs) from patients with advanced PC in order to find a molecular signature predictive of response to therapy. We analyzed samples from 21 patients with advanced PC, all receiving first-line treatment with gemcitabine + nab-paclitaxel. Isolated EVs have been analyzed, and the results of laboratory have been matched with clinical data in order to investigate possible predictive factors. EV concentration and size were similar between responder and non-responder patients. Analysis of 37 EV surface epitopes showed a decreased expression of SSEA4 and CD81 in responder patients. We detected more than 450 expressed miRNAs in EVs. A comparative survey between responder and non-responder patients showed that at least 44 miRNAs were differently expressed. Some of these miRNAs have already been observed in relation to the survival and gemcitabine sensitivity of tumor cells. In conclusion, we showed the ability of our approach to identify EV-derived biomarkers with predictive value for therapy response in PC. Our findings are worthy of further investigation, including the analysis of samples from patients treated with different schedules and in different settings.

Citing Articles

miR-6855-5p Enhances Radioresistance and Promotes Migration of Pancreatic Cancer by Inducing Epithelial-Mesenchymal Transition via Suppressing FOXA1: Potential of Plasma Exosomal miR-6855-5p as an Indicator of Radiosensitivity in Patients with....

Ueda H, Takahashi H, Kobayashi S, Kubo M, Sasaki K, Iwagami Y Ann Surg Oncol. 2024; 32(2):720-735.

PMID: 39269634 DOI: 10.1245/s10434-024-16115-w.

Extracellular vesicles in pancreatic cancer: a new era in precision medicine.

Panda A, Falasca M, Ragunath K Transl Gastroenterol Hepatol. 2024; 9:29.

PMID: 38716212 PMC: 11074477. DOI: 10.21037/tgh-23-53.

Extracellular Vesicles, Circulating Tumor Cells, and Immune Checkpoint Inhibitors: Hints and Promises.

Bandini S, Ulivi P, Rossi T Cells. 2024; 13(4.

PMID: 38391950 PMC: 10887032. DOI: 10.3390/cells13040337.

Pancreatic Cancer Health Disparity: Pharmacologic Anthropology.

Wall N, Fuller R, Morcos A, De Leon M Cancers (Basel). 2023; 15(20).

PMID: 37894437 PMC: 10605341. DOI: 10.3390/cancers15205070.

References

Hu B, Qiu-Lan H, Lei R, Shi C, Jiang H, Qin S . Interleukin-9 Promotes Pancreatic Cancer Cells Proliferation and Migration via the miR-200a/Beta-Catenin Axis. Biomed Res Int. 2017; 2017:2831056. PMC: 5352879. DOI: 10.1155/2017/2831056. View

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

Richards K, Zeleniak A, Fishel M, Wu J, Littlepage L, Hill R . Cancer-associated fibroblast exosomes regulate survival and proliferation of pancreatic cancer cells. Oncogene. 2016; 36(13):1770-1778. PMC: 5366272. DOI: 10.1038/onc.2016.353. View

Xu L, Li Q, Xu D, Wang Q, An Y, Du Q . hsa-miR-141 downregulates TM4SF1 to inhibit pancreatic cancer cell invasion and migration. Int J Oncol. 2013; 44(2):459-66. DOI: 10.3892/ijo.2013.2189. View

Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y . FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011; 364(19):1817-25. DOI: 10.1056/NEJMoa1011923. View

Rawat M, Kadian K, Gupta Y, Kumar A, Chain P, Kovbasnjuk O . MicroRNA in Pancreatic Cancer: From Biology to Therapeutic Potential. Genes (Basel). 2019; 10(10). PMC: 6827136. DOI: 10.3390/genes10100752. View

Funamizu N, Lacy C, Kamada M, Yanaga K, Manome Y . MicroRNA-200b and -301 are associated with gemcitabine response as biomarkers in pancreatic carcinoma cells. Int J Oncol. 2019; 54(3):991-1000. DOI: 10.3892/ijo.2019.4676. View

Pasini L, Vannini I, Ulivi P, Tebaldi M, Petracci E, Fabbri F . Comparative Analysis of Free-Circulating and Vesicle-Associated Plasma microRNAs of Healthy Controls and Early-Stage Lung Cancer Patients. Pharmaceutics. 2022; 14(10). PMC: 9610033. DOI: 10.3390/pharmaceutics14102029. View

Quagliano A, Gopalakrishnapillai A, Kolb E, Barwe S . CD81 knockout promotes chemosensitivity and disrupts in vivo homing and engraftment in acute lymphoblastic leukemia. Blood Adv. 2020; 4(18):4393-4405. PMC: 7509883. DOI: 10.1182/bloodadvances.2020001592. View

10.

Wattenberg M, Asch D, Yu S, ODwyer P, Domchek S, Nathanson K . Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation. Br J Cancer. 2019; 122(3):333-339. PMC: 7000723. DOI: 10.1038/s41416-019-0582-7. View

11.

Yu J, Ohuchida K, Mizumoto K, Sato N, Kayashima T, Fujita H . MicroRNA, hsa-miR-200c, is an independent prognostic factor in pancreatic cancer and its upregulation inhibits pancreatic cancer invasion but increases cell proliferation. Mol Cancer. 2010; 9:169. PMC: 2909980. DOI: 10.1186/1476-4598-9-169. View

12.

Golan T, Kanji Z, Epelbaum R, Devaud N, Dagan E, Holter S . Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers. Br J Cancer. 2014; 111(6):1132-8. PMC: 4453851. DOI: 10.1038/bjc.2014.418. View

13.

Lin C, Wang Y, Lai T, Hsu T, Han S, Wu H . Homogeneous antibody and CAR-T cells with improved effector functions targeting SSEA-4 glycan on pancreatic cancer. Proc Natl Acad Sci U S A. 2021; 118(50). PMC: 8685897. DOI: 10.1073/pnas.2114774118. View

14.

Wang Z, Chen Y, Lin Y, Wang X, Cui X, Zhang Z . Novel crosstalk between KLF4 and ZEB1 regulates gemcitabine resistance in pancreatic ductal adenocarcinoma. Int J Oncol. 2017; 51(4):1239-1248. DOI: 10.3892/ijo.2017.4099. View

15.

Siegel R, Miller K, Fuchs H, Jemal A . Cancer statistics, 2022. CA Cancer J Clin. 2022; 72(1):7-33. DOI: 10.3322/caac.21708. View

16.

Shamblott M, Axelman J, Wang S, Bugg E, LITTLEFIELD J, Donovan P . Derivation of pluripotent stem cells from cultured human primordial germ cells. Proc Natl Acad Sci U S A. 1998; 95(23):13726-31. PMC: 24887. DOI: 10.1073/pnas.95.23.13726. View

17.

Heredia-Soto V, Rodriguez-Salas N, Feliu J . Liquid Biopsy in Pancreatic Cancer: Are We Ready to Apply It in the Clinical Practice?. Cancers (Basel). 2021; 13(8). PMC: 8074327. DOI: 10.3390/cancers13081986. View

18.

Xu R, Rai A, Chen M, Suwakulsiri W, Greening D, Simpson R . Extracellular vesicles in cancer - implications for future improvements in cancer care. Nat Rev Clin Oncol. 2018; 15(10):617-638. DOI: 10.1038/s41571-018-0036-9. View

19.

Qiu J, Yang G, Feng M, Zheng S, Cao Z, You L . Extracellular vesicles as mediators of the progression and chemoresistance of pancreatic cancer and their potential clinical applications. Mol Cancer. 2018; 17(1):2. PMC: 5756395. DOI: 10.1186/s12943-017-0755-z. View

20.

Song B, Zheng K, Ma H, Liu A, Jing W, Shao C . miR-429 determines poor outcome and inhibits pancreatic ductal adenocarcinoma growth by targeting TBK1. Cell Physiol Biochem. 2015; 35(5):1846-56. DOI: 10.1159/000373995. View